T Nicholaou, W Chen, ID Davis… - Cancer Immunology, …, 2011 - Springer Abstract Background NY-ESO-1 protein formulated in ISCOMATRIX™ results in CD4+, CD8+ T cell and antibody-mediated immunity. We evaluated persistence of immunity, relapse-free survival and tumour antigen expression upon relapse in patients vaccinated ... Related articles - All 2 versions
KS Peggs, K Thomson, E Samuel… - Clinical Infectious …, 2011 - cid.oxfordjournals.org Results. Cell selection was successful in all cases, yielding a product biased towards CD4 + over CD8 + T cells. The target cell dose of 1 × 10 4 CD3 + T cells/kg of recipient weight contained a median of 2840 cytomegalovirus-specific CD4 + cells/kg and 630 ... Cited by 4 - Related articles - All 5 versions
H Shirota… - Cancer Immunology, Immunotherapy, 2011 - Springer Abstract The primary goal of cancer immunotherapy is to elicit an immune response capable of eradicating established tumors and preventing tumor metastasis. One strategy to achieve this goal utilizes whole killed tumor cells as the primary immunogen. Killed tumor cells ... Related articles - All 4 versions
W Borkowsky, EJ McFarland, R Yogev… - Clinical and Vaccine …, 2011 - Am Soc Microbiol Page 1. 1 Correlation of HIV-specificImmunity, Viral Control and Diversification 1 following Planned Multiple Exposures to Autologous HIV in a Pediatric 2 Population 3 4 ... 14 Short Title : HIV Diversity and CD8-specificimmunity 15 16 17 18 19 20 21 22 23 ...
V Dasarai, C Smith, J Zhong… - Journal of General …, 2011 - Soc General Microbiol ... immune stimulating complex induces specificimmunity against multiple 2 strains of cytomegalovirus 3 4 ... CMV gB-specific T cell immunity using intracellular cytokine analysis, and humoral responses 91 were assessed using gB ELISA. ... All 2 versions
沪公网安备号：31010402006960 （网站）31010405000484 （蝌蝌APP）
安全保密
